semaglutide side chain Chain,octadecanedioic Acid,Fatty Acid Starting structure of semaglutide used

Triplet arm : Higher adverse events28.3% discontinued, ~10% experienced severe treatment-emergent adverse events (TEAEs), including two deaths (one from cardiac arrest

Monitoring : Regular monitoring of blood glucose levels, hemoglobin A1c labs, weight loss, and any potential side effects during the transition period are critical

GLP-1: The Incretin Hormone GLP-1 is an essential hormone released during the digestion process to help regulate blood sugar levels

Supports HbA1c reduction

Additionally, if patients are monitoring only body weight without considering other metabolic improvements (such as reduced fasting glucose, decreased appetite, or improved postprandial glucose excursions), they may underestimate the medication's effects

Even if semaglutide is already lowering your blood sugar, it may take 12 weeks or more to see changes reflected in your HbA1C test